Duncan R, Kopecková-Rejmanová P, Strohalm J, Hume I, Cable H C, Pohl J, Lloyd J B, Kopecek J
Br J Cancer. 1987 Feb;55(2):165-74. doi: 10.1038/bjc.1987.33.
During recent years N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers have been developed as targetable drug carriers. These soluble synthetic polymers are internalized by cells by pinocytosis and they can be tailor-made to include peptidyl side-chains degradable intracellularly by specific lysosomal enzymes. Thus they provide the opportunity fo achieve controlled intracellular delivery of anticancer agents. The anthracycline antibiotic daunomycin, and protein synthesis inhibitor puromycin, were bound to HPMA copolymers via several different peptide side-chains, including Gly-Gly, Gly-Phe-Leu-Gly and Gly-Phe-Phe-Leu. Incubation of polymer-drug conjugates with isolated lysosomal enzymes (either a mixture of rat liver lysosomal enzymes or purified thiol-dependent lysosomal proteinases, cathepsins L and B) showed that significant release of drug occurred over 20 h, more than 20% of daunomycin and more than 80% of puromycin being liberated. To test their pharmacological activity conjugates were incubated with either the mouse leukaemia L1210, or the human lymphoblastoid leukaemia CCRF in vitro. The conjugates tested were all less effective than free daunomycin, but they showed differential toxicity against L1210 depending on the aminoacid sequence of their drug-polymer linkage. Inclusion of fucosylamine-terminating side-chains into the HPMA copolymer structure increased the affinity of conjugates for the L1210 cell membrane and resulted in increased toxicity. In contrast HPMA-daunomycin conjugates with or without fucosylamine affected CCRF cells equally, but this cell line was more sensitive than the mouse leukaemia to both free and polymer-bound daunomycin. Incubation of L1210 cells in polymer-bound daunomycin for 72 h, followed by plating cells out in low density in drug-free medium, showed that a concentration of polymer-bound drug (184 micrograms ml-1) could be selected to achieve a cytotoxic effect.
近年来,N-(2-羟丙基)甲基丙烯酰胺(HPMA)共聚物已被开发为可靶向的药物载体。这些可溶性合成聚合物通过胞饮作用被细胞内化,并且可以进行定制,使其包含可被特定溶酶体酶在细胞内降解的肽基侧链。因此,它们为实现抗癌药物的可控细胞内递送提供了机会。蒽环类抗生素柔红霉素和蛋白质合成抑制剂嘌呤霉素通过几种不同的肽侧链与HPMA共聚物结合,包括甘氨酰-甘氨酸、甘氨酰-苯丙氨酰-亮氨酰-甘氨酸和甘氨酰-苯丙氨酰-苯丙氨酰-亮氨酸。将聚合物-药物缀合物与分离的溶酶体酶(大鼠肝溶酶体酶混合物或纯化的硫醇依赖性溶酶体蛋白酶,组织蛋白酶L和B)一起孵育表明,药物在20小时内发生了显著释放,超过20%的柔红霉素和超过80%的嘌呤霉素被释放出来。为了测试它们的药理活性,将缀合物与小鼠白血病L1210或人淋巴母细胞白血病CCRF在体外一起孵育。所测试的缀合物都比游离柔红霉素的效果差,但它们对L1210显示出取决于其药物-聚合物连接氨基酸序列的差异毒性。在HPMA共聚物结构中包含岩藻糖胺末端侧链增加了缀合物对L1210细胞膜的亲和力,并导致毒性增加。相比之下,有或没有岩藻糖胺的HPMA-柔红霉素缀合物对CCRF细胞的影响相同,但该细胞系比小鼠白血病对游离和聚合物结合的柔红霉素都更敏感。将L1210细胞在聚合物结合的柔红霉素中孵育72小时,然后在无药物培养基中低密度接种细胞,结果表明可以选择聚合物结合药物的浓度(184微克/毫升)来实现细胞毒性作用。